Amir Englund

2.2k total citations · 1 hit paper
27 papers, 1.4k citations indexed

About

Amir Englund is a scholar working on Pharmacology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Amir Englund has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmacology, 10 papers in Psychiatry and Mental health and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Amir Englund's work include Cannabis and Cannabinoid Research (23 papers), Schizophrenia research and treatment (8 papers) and Bipolar Disorder and Treatment (6 papers). Amir Englund is often cited by papers focused on Cannabis and Cannabinoid Research (23 papers), Schizophrenia research and treatment (8 papers) and Bipolar Disorder and Treatment (6 papers). Amir Englund collaborates with scholars based in United Kingdom, Australia and United States. Amir Englund's co-authors include Robin Murray, Philip McGuire, Tom P. Freeman, Marta Di Forti, Paul D. Morrison, Edward Chesney, Harriet Quigley, Diego Quattrone, Dominic Oliver and James Stone and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neuroscience & Biobehavioral Reviews and Neuropsychopharmacology.

In The Last Decade

Amir Englund

27 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

2012 361 citations Amir Englund, Paul D. Morrison et al. Journal of Psychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amir Englund United Kingdom	16	1.2k	366	311	224	222	27	1.4k
Gráinne Schäfer United Kingdom	10	959 0.8×	372 1.0×	205 0.7×	254 1.1×	169 0.8×	12	1.1k
Gabriel Braley United States	9	1.4k 1.2×	795 2.2×	477 1.5×	318 1.4×	226 1.0×	10	1.7k
Hendrika H. van Hell Netherlands	15	945 0.8×	548 1.5×	211 0.7×	419 1.9×	152 0.7×	21	1.3k
Kelly A. Sagar United States	17	770 0.6×	246 0.7×	209 0.7×	223 1.0×	188 0.8×	33	1.0k
Douglas L. Boggs United States	18	711 0.6×	268 0.7×	989 3.2×	171 0.8×	275 1.2×	30	1.8k
Rebecca Crean United States	13	581 0.5×	412 1.1×	133 0.4×	225 1.0×	198 0.9×	17	1.1k
Mallory Loflin United States	15	846 0.7×	109 0.3×	117 0.4×	109 0.5×	231 1.0×	24	968
Will Lawn United Kingdom	20	587 0.5×	472 1.3×	110 0.4×	238 1.1×	482 2.2×	60	1.2k
Dino Zagic Australia	7	633 0.5×	126 0.3×	141 0.5×	94 0.4×	172 0.8×	11	811
Nicolas J. Schlienz United States	17	594 0.5×	170 0.5×	76 0.2×	129 0.6×	124 0.6×	34	873

Countries citing papers authored by Amir Englund

Since Specialization

Citations

This map shows the geographic impact of Amir Englund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Englund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Englund more than expected).

Fields of papers citing papers by Amir Englund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amir Englund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Englund. The network helps show where Amir Englund may publish in the future.

Co-authorship network of co-authors of Amir Englund

This figure shows the co-authorship network connecting the top 25 collaborators of Amir Englund. A scholar is included among the top collaborators of Amir Englund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amir Englund. Amir Englund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chesney, Edward, Dominic Oliver, Alex M. Dickens, et al.. (2025). Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial. Neuropsychopharmacology. 50(12). 1759–1767. 1 indexed citations

Chesney, Edward, Dominic Oliver, Simiao Wang, et al.. (2024). Exploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms. Frontiers in Psychiatry. 15. 1309868–1309868. 1 indexed citations

Oliver, Dominic, Edward Chesney, Alexis E. Cullen, et al.. (2024). Exploring causal mechanisms of psychosis risk. Neuroscience & Biobehavioral Reviews. 162. 105699–105699. 10 indexed citations

Lawn, Will, Claire Mokrysz, Anna Borissova, et al.. (2023). The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction. 118(7). 1282–1294. 24 indexed citations

Oliver, Dominic, Amir Englund, Edward Chesney, et al.. (2023). Cannabidiol does not attenuate acute delta‐9‐tetrahydrocannabinol‐induced attentional bias in healthy volunteers: A randomised, double‐blind, cross‐over study. Addiction. 119(2). 322–333. 3 indexed citations

Rafei, Parnian, Amir Englund, Valentina Lorenzetti, et al.. (2023). Transcultural Aspects of Cannabis Use: a Descriptive Overview of Cannabis Use across Cultures. Current Addiction Reports. 10(3). 458–471. 7 indexed citations

Hobin, Erin, Ashini Weerasinghe, Sadie Boniface, et al.. (2023). Co-use of cannabis and alcohol before and after Canada legalized nonmedical cannabis: A repeat cross-sectional study. Journal of Psychopharmacology. 37(5). 462–471. 6 indexed citations

Englund, Amir, Dominic Oliver, Edward Chesney, et al.. (2022). Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology. 48(6). 869–876. 69 indexed citations

Englund, Amir, et al.. (2022). Could COVID expand the future of addiction research? Long‐term implications in the pandemic era. Addiction. 117(8). 2135–2140. 9 indexed citations

10.

Englund, Amir, Edward Chesney, Dominic Oliver, et al.. (2022). Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study. Cannabis and Cannabinoid Research. 9(1). 188–198. 7 indexed citations

11.

Lorenzetti, Valentina, et al.. (2022). Effects of cannabinoids on resting state functional brain connectivity: A systematic review. Neuroscience & Biobehavioral Reviews. 145. 105014–105014. 7 indexed citations

12.

Claridge, Hugh, et al.. (2021). Synthetic Cannabinoid-Related Deaths in England, 2012–2019. Cannabis and Cannabinoid Research. 7(4). 516–525. 25 indexed citations

13.

Oliver, Dominic, Giulia Spada, Amir Englund, et al.. (2020). Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. Schizophrenia Research. 226. 176–183. 17 indexed citations

14.

Chesney, Edward, Dominic Oliver, Alastair Green, et al.. (2020). Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 45(11). 1799–1806. 175 indexed citations

15.

Thomsen, Kristine Rømer, Christian Lindholst, Birgitte Thylstrup, et al.. (2019). Changes in the composition of cannabis from 2000–2017 in Denmark: Analysis of confiscated samples of cannabis resin.. Experimental and Clinical Psychopharmacology. 27(4). 402–411. 30 indexed citations

16.

Murray, Robin, Amir Englund, Anissa Abi‐Dargham, et al.. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology. 124. 89–104. 123 indexed citations

17.

Englund, Amir, Tom P. Freeman, Robin Murray, & Philip McGuire. (2017). Can we make cannabis safer?. The Lancet Psychiatry. 4(8). 643–648. 107 indexed citations

18.

Englund, Amir, Paul D. Morrison, Judith Nottage, et al.. (2012). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology. 27(1). 19–27. 361 indexed citations breakdown →

19.

Englund, Amir, James Stone, & Paul D. Morrison. (2012). Cannabis in the Arm: What Can we Learn from Intravenous Cannabinoid Studies?. Current Pharmaceutical Design. 18(32). 4906–4914. 15 indexed citations

20.

Morrison, D. P., et al.. (1990). Safety evaluation in both short‐ and long‐term treatment of schizophrenia with remoxipride. Acta Psychiatrica Scandinavica. 82(S358). 164–169. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact